Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a New Dilution and Injection Volume of AbobotulinumtoxinA for the Treatment of Moderate to Severe Glabellar Lines
Conditions
Interventions
AbobotulinumtoxinA
Placebo
Locations
11
United States
Galderma Study Site
Redondo Beach, California, United States
Galderma Study Site
San Diego, California, United States
Galderma Study Site
Westport, Connecticut, United States
Galderma Study Site
Washington D.C., District of Columbia, United States
Galderma Study Site
Coral Gables, Florida, United States
Galderma Study Site
Atlanta, Georgia, United States
Start Date
June 17, 2019
Primary Completion Date
September 27, 2019
Completion Date
April 16, 2020
Last Updated
August 26, 2022
NCT05481931
NCT06411002
NCT05146999
NCT05148000
NCT05277337
NCT04249583
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions